Patents Examined by Deborah C. Lambkin
  • Process for preparing glycidylphthalimide
    Patent number: 7135576
    Abstract: A process for preparing glycidylphtalimide or it optically active compound by reacting a phthalimide alkalimetal salt with an epihalohydrin or an optically active epihalohydrin in an alcohol solvent; or by reacting phthalimide with an epihalohydrin or an optically active epihalohydrin in the presence of an alkali metal carbonate, an alkali metal hydrogencarbonate or a quaternary ammonium salt to obtain a N-(3-halogeno-2-hydroxypropyl)phthalimide and then by cyclizing the product with an alkali metal alkoxide.
    Type: Grant
    Filed: January 7, 2005
    Date of Patent: November 14, 2006
    Assignee: Daiso Co., Ltd.
    Inventors: Yoshiro Furukawa, Yasushi Miki
  • Inhibitors of cruzipain and other cysteine proteases
    Patent number: 7132449
    Abstract: Compounds of general formula (I): wherein R1, R2, Y, (X)o, (W)n, (V)m, Z and U are as defined in the specification, are inhibitors of cruzipain and other cysteine protease inhibitors and are useful as therapeutic agents, for example in Chagas' disease, or for validating therapeutic target compounds.
    Type: Grant
    Filed: January 7, 2002
    Date of Patent: November 7, 2006
    Assignee: Amura Therapeutics Limited
    Inventor: Martin Quibell
  • Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
    Patent number: 7132432
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein the variables L, Z0, R1, R4, R5, and R11 are defined are as defined herein, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), aggrecanase, or a combination thereof.
    Type: Grant
    Filed: June 2, 2004
    Date of Patent: November 7, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jingwu Duan, Chu-Biao Xue, James Sheppeck, Bin Jiang, Lihua Chen
  • Conductive compound, electrode and sensor containing the same, and target molecule detection method using the sensor
    Patent number: 7129363
    Abstract: A conductive compound of formula (I) below, an electrode coated with the conductive compound, a sensor including the electrode, and a target molecule detection method using the sensor are provided: wherein Y is a carbonyl or —NH—; R is one of H, OH, a leaving group, and a probe group; l is an integer from 3 to 6; m is an integer from 1 to 4; and n is an integer from 0 to 3.
    Type: Grant
    Filed: March 1, 2004
    Date of Patent: October 31, 2006
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Jung-im Han, Jun-hoe Cha, Geun-bae Lim
  • Mono-, oligo- and polymers comprising fluorene and aryl groups
    Patent number: 7126013
    Abstract: Mono-, oligo- or polymers comprising at least one 9-H,H-fluorene group and at least one arylene group are suitable for use as semiconductors or charge transport materials in optical, electrooptical or electronic devices including field effect transistors, electroluminescent, photovoltaic and sensor devices.
    Type: Grant
    Filed: March 8, 2004
    Date of Patent: October 24, 2006
    Assignee: Merck Patent GmbH
    Inventors: Martin Heeney, Steven Tierney, Marcus Thompson, Iain Mc Culloch
  • Process for the preparation of thioxanthones
    Patent number: 7126011
    Abstract: Processes are described for the preparation of thioxanthones (Formula I). A reactant mixture of a 2-chlorothiobenzoyl chloride (Formula II) and an aromatic compound (Formula III) is added to a slurry of a Friedel-Crafts catalyst in an organic Friedel-Crafts solvent.
    Type: Grant
    Filed: April 7, 2003
    Date of Patent: October 24, 2006
    Assignee: Prom Limited
    Inventor: Carsten Berg
  • Process for preparing optically active 3-(methylamino)-1-(2-thienyl) propan-1-ol and intermediates for preparation
    Patent number: 7119211
    Abstract: Disclosed is a process for commercial preparation of 3-(methylamino)-1-(2-thienyl)propan-1-ol (hereinafter abbreviated as “MMAA”) of the formula below: The process is carried out by the diastereomeric salt formation method using optically active mandelic acid or its derivatives, or an optically active tartaric acid derivative as the resolving agent. The product compound, diastereomeric satls, is useful as the intermediate for producing pharmaceuticals, such as duloxetine.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: October 10, 2006
    Assignee: Yamakawa Chemical Industry Co., Ltd.
    Inventors: Kenichi Sakai, Rumiko Sakurai, Atsushi Yuzawa, Kaoru Hatahira
  • Aspartyl protease inhibitors
    Patent number: 7115652
    Abstract: The present invention provides compounds having the formula: wherein R1, R?, R2, R3, R3?, R4, X1, X2 and X3 are as defined herein, and pharmaceutical compositions thereof. The present invention also provides methods of inhibiting proteases, more specifically aspartyl proteases. In certain embodiments, compounds inhibit BACE (?-site APP-cleaving enzyme), and thus are useful in the treatment or prevention of a disease characterized by ?-amyloid deposits in the brain (including, but not limited to, Alzheimer's Disease). The present invention also provides methods for preparing compounds of the invention.
    Type: Grant
    Filed: December 10, 2003
    Date of Patent: October 3, 2006
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventor: Wenjin Yang
  • Method of treating a condition by administering a prostaglandin derivative
    Patent number: 7115659
    Abstract: 2-Decarboxy-2-phosphinico prostaglandin derivatives are disclosed. These derivatives comprise a modified ?-chain and an ?-chain bonded to a ring structure. The modified ?-chain has a 2-decarboxy-2-phosphinico group. The derivatives can be used to treat a variety of pharmaceutical and cosmetic conditions.
    Type: Grant
    Filed: January 14, 2005
    Date of Patent: October 3, 2006
    Assignee: The Procter & Gamble Company
    Inventor: Mitchell Anthony DeLong
  • Heterocyclic modulators of nuclear receptors
    Patent number: 7115640
    Abstract: Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. In certain embodiments, the compounds are thiazolidinone derivatives.
    Type: Grant
    Filed: November 18, 2003
    Date of Patent: October 3, 2006
    Assignee: X-Ceptor Therapeutics, Inc.
    Inventors: Richard Martin, Brenton T Flatt, Jeffrey D Kahl, Tie-Lin Wang
  • Substituted benzopyran derivatives for the treatment of inflammation
    Patent number: 7109211
    Abstract: A class of benzopyran, derivatives is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula I? wherein X, A1, A2, A3, A4, R, R?, R1 and R2 are as described in the specification.
    Type: Grant
    Filed: August 19, 2004
    Date of Patent: September 19, 2006
    Assignee: Pharmacia Corporation (of Pfizer, Inc.)
    Inventors: Jeffery S Carter, Mark G Obukowicz, Balekudru Devadas, John J Talley, David L Brown, Matthew J Graneto, Stephen R Bertenshaw, Donald J. Rogier, Jr., Srinivasan Raj Nagarajan, Cathleen E Hanau, Susan J Hartmann, Cindy L Ludwig, Suzanne Metz, Donald E Korte
  • Fluorinated ?-bridge second order nonlinear optical chromophores and electro-optic devices therefrom
    Patent number: 7109355
    Abstract: A nonlinear optical chromophore having the formula D-?-A, wherein ? is a ? bridge including a thiophene ring having oxygen atoms bonded directly to the 3 and 4 positions of the thiophene ring, D is a donor, A is an acceptor, and the oxygen atoms are further substituted with a fluorinated group comprising at least three fluorines is described. Some examples of fluorinated groups comprising at least three fluorine atoms are 2,2,2-trifluoroethyl; 2,2,3,3,3-pentafluoropropyl; 2,2,3,3,4,4,4-heptafluorobutyl; 2,2,3,3,4,4,5,5,5-octafluoropentyl; 3,3,4,4,-5,5,6,6,7,7,8,8,8-tridecafluoro-1-octyl; 2,2,3,3,4,4,5,5,6,6,7,7,8,8,8 -pentadecafluorooctyl; 1-trifluoromethyl-2,2,2-trifluoroethyl; 1-trifluoromethyl-2,2,3,3,3 -pentafluoropropyl; 2,3,4,5,6-pentafluorobenzyl; and (2,3,4,5,6-pentafluorophenyl)ethyl.
    Type: Grant
    Filed: January 14, 2004
    Date of Patent: September 19, 2006
    Assignee: Lumera Corporation
    Inventor: Diyun Huang
  • N-phenyl-pyrrol bisphosphane compounds and the metal complexes of the same
    Patent number: 7109346
    Abstract: N-Phenylpyrrolebisphosphines of the formula I metal complexes of these N-phenylpyrrolebisphosphines and their use in metal-catalyzed reactions.
    Type: Grant
    Filed: December 12, 2001
    Date of Patent: September 19, 2006
    Assignee: OXENO Olefinchemie GmbH & Co. KG
    Inventors: Matthias Beller, Ralf Jackstell, Holger Klein, Detlef Heller, Hans-Joachim Drexler, Klaus-Diether Wiese, Dirk Roettger
  • Process for preparing 5,6-dihydro-4-(S)-(ethylamino)-6-(S) methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide HCl
    Patent number: 7109353
    Abstract: The present invention relates to an improved process for the preparation of 5,6-dihydro-4-(S)-(ethylamino)-6-(S)methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide hydrochloride of formula (I) commonly known as Dorzolamide Hydrochloride useful as an agent to reduce intraoccular pressure by inhibiting carbonic anhydrase enzyme
    Type: Grant
    Filed: December 28, 2004
    Date of Patent: September 19, 2006
    Assignee: Council of Scientific and Industrial Research
    Inventors: Mukund Keshao Gurjar, Madhusudan Nagorao Deshmukh, Vincent Paul, Venkatasubramaniam Radhakrishnan Tarur, Dhananjay Govind Sathe, Santosh Pratap Pardeshi, Sanjay Janardhan Naik, Tushar Anil Naik
  • Fused pyrrolecarboxamides; GABA brain receptor ligands
    Patent number: 7109351
    Abstract: Substituted pyrrolecarboxamide compounds are disclosed. These compounds are highly selective agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Alzheimer's dementia, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABAA receptors in tissue samples.
    Type: Grant
    Filed: August 30, 2000
    Date of Patent: September 19, 2006
    Assignee: Neurogen Corporation
    Inventors: Pamela Albaugh, Kenneth Shaw, Alan Hutchison
  • Preparation of 2,2?-di(3,4-ethylenedioxythiophene)s
    Patent number: 7102016
    Abstract: The invention relates to a process for preparing compounds of the general formula (I) to novel compounds of this substance class and also to their use as important precursors or for preparing important precursors for ?-conjugated polymers.
    Type: Grant
    Filed: December 4, 2003
    Date of Patent: September 5, 2006
    Assignee: H. C. Starck GmbH
    Inventor: Knud Reuter
  • Processes to prepare small molecular thiophene compounds
    Patent number: 7102017
    Abstract: A process composed of subjecting a reaction mixture comprising a reaction medium, a coupling agent, and a precursor to a coupling temperature to preferentially form a desired small molecular thiophene compound in a single-step synthesis, wherein the precursor consists of: (i) an optional divalent linkage, and (ii) a plurality of thiophene units, each thiophene unit being represented by structure (A) wherein each thiophene unit is bonded at either or both of the second ring position and the fifth ring position.
    Type: Grant
    Filed: June 10, 2004
    Date of Patent: September 5, 2006
    Assignee: Xerox Corporation
    Inventors: Ping Liu, Yiliang Wu, Beng S. Ong, Maria Birau
  • Peptidic compounds as cysteine protease inhibitors
    Patent number: 7101880
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Grant
    Filed: June 24, 2003
    Date of Patent: September 5, 2006
    Assignee: Schering Aktiengesellschaft
    Inventors: Michael Graupe, John O. Link
  • Thiophene hydroxamic acid derivatives
    Patent number: 7098241
    Abstract: The (R) and (S) enantiomers of a compound of formula I are novel antiproliferative therapeutic agents. These compounds have HDAC inhibitor activity and are useful in the treatment of cancer. Also disclosed are methods of making and using compounds of formula (I), as well as pharmaceutical compositions containing compounds of formula (I).
    Type: Grant
    Filed: December 10, 2003
    Date of Patent: August 29, 2006
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Adelbert Grossmann, Frank Herting, Matthias Koerner, Klaus-Peter Kuenkele, Anja Limberg, Olaf Mundigl, Ulrich Tibes
  • Dipeptidyl peptidase inhibitors for the treatment of diabetes
    Patent number: 7098239
    Abstract: Compounds having Formula I, including pharmaceutically acceptable salts and prodrugs thereof: (Formula I) are inhibitors of the dipep tidyl peptidase-IV enzyme (DP-IV), and are useful in the treatment of DP-IV mediated diseases and conditions, such as non-insulin dependent diabetes mellitus.
    Type: Grant
    Filed: June 19, 2002
    Date of Patent: August 29, 2006
    Assignee: Merck & Co., Inc
    Inventors: Scott D. Edmondson, Emma Parmee, Ann E. Weber, Jinyou Xu